CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
Francesco Schettini(Target (United States)), Lucia Del Mastro(Ospedale Policlinico San Martino), Pietro De Placido(University of Naples Federico II), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Grazia Arpino(University of Naples Federico II), Carmen G. Rea(University of Naples Federico II), Luigi Formisano(University of Naples Federico II), Mario Giuliano(Regione Campania), Sabino De Placido, Irene De Santo(University of Naples Federico II), Fabio Puglisi(University of Udine)
Cited by 205
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830